Literature DB >> 2864784

Characterization of the contractile effect of neuropeptide Y in feline cerebral arteries.

L Edvinsson.   

Abstract

The action of neuropeptide Y (NPY), which coexists with noradrenaline (NA) in perivascular sympathetic nerves, has been examined on feline cerebrovascular smooth muscle using a sensitive in vitro system. The direct cerebrovascular responses of peptides with structural similarities with NPY, peptide YY (PYY), avian (APP), and bovine (BPP) and human (HPP) pancreatic polypeptides, have been compared with that of NPY on isolated feline cerebral arteries. The relative potency for contractions induced by the peptides is: NPY, PYY greater than APP greater than BPP, HPP. The alpha-adrenoceptor antagonist rauwolscine, which blocked the response to noradrenaline (NA), had no effect on NPY-induced contractions. Neuropeptide Y significantly potentiated contractions induced by 10(-6) M NA, but not by 10(-5) M. Withdrawal of Ca2+ from the extracellular medium for 30 min reduced the contractile response to NPY in cerebral vessels by about 80%. Subsequent readdition of Ca2+ caused reproducible contractions which were inhibited by the calcium entry blocker nimodipine. Nimodipine also relaxed isolated middle cerebral artery segments contracted by NPY and NA in a concentration-dependent manner. The data suggest that NPY mediates contraction of cerebrovascular smooth muscle via a mechanism that is dependent on the concentration of extracellular calcium.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2864784     DOI: 10.1111/j.1748-1716.1985.tb07690.x

Source DB:  PubMed          Journal:  Acta Physiol Scand        ISSN: 0001-6772


  15 in total

1.  Changes in the levels of neuropeptide Y-LI in the external jugular vein in connection with vasoconstriction following subarachnoid haemorrhage in man. Involvement of sympathetic neuropeptide Y in cerebral vasospasm.

Authors:  R Juul; L Edvinsson; T A Fredriksen; R Ekman; A O Brubakk; S E Gisvold
Journal:  Acta Neurochir (Wien)       Date:  1990       Impact factor: 2.216

2.  Neuropeptide Y acts at Y1 receptors in the rostral ventral medulla to inhibit neuropathic pain.

Authors:  Bradley K Taylor; Sarang S Abhyankar; Ngoc-Tram T Vo; Christopher L Kriedt; Sajay B Churi; Janice H Urban
Journal:  Pain       Date:  2007-02-02       Impact factor: 6.961

3.  Potentiation by neuropeptide Y of vasoconstriction in rat resistance arteries.

Authors:  R Andriantsitohaina; J C Stoclet
Journal:  Br J Pharmacol       Date:  1988-10       Impact factor: 8.739

4.  Adenosine 5'-triphosphate and neuropeptide Y are co-transmitters in conjunction with noradrenaline in the human saphenous vein.

Authors:  H Racchi; M J Irarrázabal; M Howard; S Morán; R Zalaquett; J P Huidobro-Toro
Journal:  Br J Pharmacol       Date:  1999-03       Impact factor: 8.739

Review 5.  The crosstalk between autonomic nervous system and blood vessels.

Authors:  Yulan Sheng; Li Zhu
Journal:  Int J Physiol Pathophysiol Pharmacol       Date:  2018-03-10

6.  Chemical sympathectomy reveals pre- and postsynaptic effects of neuropeptide Y (NPY) in the cardiovascular system.

Authors:  Y Mabe; R Pérez; K Tatemoto; J P Huidobro-Toro
Journal:  Experientia       Date:  1987-09-15

7.  Sympathetic nervous system-targeted neuropeptide Y overexpression in mice enhances neointimal formation in response to vascular injury.

Authors:  Suvi T Ruohonen; Ken Abe; Mia Kero; Laura Toukola; Saku Ruohonen; Matias Röyttä; Markku Koulu; Ullamari Pesonen; Zofia Zukowska; Eriika Savontaus
Journal:  Peptides       Date:  2008-12-24       Impact factor: 3.750

Review 8.  Peptides in the mammalian cardiovascular system.

Authors:  J Wharton; S Gulbenkian
Journal:  Experientia       Date:  1987-07-15

9.  Transmural regulation of myocardial perfusion by neuropeptide Y.

Authors:  D D Gutterman; D A Morgan
Journal:  Basic Res Cardiol       Date:  1995 Jul-Aug       Impact factor: 17.165

10.  The actions of neuropeptide Y and peptide YY on the hepatic arterial and portal vascular beds of the anaesthetized dog.

Authors:  R Corder; P G Withrington
Journal:  Br J Pharmacol       Date:  1988-08       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.